Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31454781 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL3949948 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL3264782 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL8812022 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL300482 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL2346412 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL17777817 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL7989762 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL3955770 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL29858099 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628668-B1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | KAKEN PHARMA CO LTD (JP) | 2023-02-22 | — | — | EP | disclosed |
| US-10829475-B2 | Production and purification methods for efinaconazole | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-11-10 | — | — | US | disclosed |
| US-20200181110-A1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | KAKEN PHARMA CO LTD (JP) | 2020-06-11 | — | — | US | disclosed |
| US-10626115-B2 | Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents | UNIVERSITE DE NANTES (FR) | 2020-04-21 | — | — | US | disclosed |
| EP-3442957-B1 | \"PROCESS FOR PREPARING INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIFUNGAL DRUGS\ | OLON SPA (IT) | 2020-01-29 | — | — | EP | disclosed |
| US-10479776-B2 | Process for the preparation of Efinaconazole | LUPIN LIMITED (IN) | 2019-11-19 | — | — | US | disclosed |
| US-20190292166-A1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-09-26 | — | — | US | disclosed |
| US-20190002467-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES CONTAINING BRIDGED NITROGEN, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | UNIVERSITE DE NANTES (FR) | 2019-01-03 | — | — | US | disclosed |
| US-20180162833-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-06-14 | — | — | US | disclosed |
| US-20180118714-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | LUPIN LIMITED (IN) | 2018-05-03 | — | — | US | disclosed |
| US-9932321-B2 | Process for the preparation of piperidine compounds | DIPHARMA FRANCIS S.R.L. (IT) | 2018-04-03 | — | — | US | disclosed |
| WO-2017178909-A1 | PROCESS FOR PREPARING INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIFUNGAL DRUGS | OLON S.P.A. (IT) | 2017-10-19 | — | — | WO | disclosed |
| US-20170129874-A1 | NOVEL IMPROVED PROCESS FOR PREPARING A TRIAZOLE ANTIFUNGAL AGENT | VIRUPAKSHA ORGANICS LTD (IN) | 2017-05-11 | — | — | US | disclosed |
| WO-2017021178-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS. | UNIVERSITE DE NANTES (FR) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017020944-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | UNIVERSITE DE NANTES (FR) | 2017-02-09 | — | — | WO | disclosed |
| US-8871942-B2 | Process for producing 1-triazole-2-butanol derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8871942-B2 | Process for producing 1-triazole-2-butanol derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20130150586-A1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150586-A1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-5789429-A | FUNGICIDE | EISAI CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162833-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | CYP3A43, CYP3A5, CYP51A1 | CYP3A4 4/4885CYP2C9 13/4885CYP2C19 12/4885 |
| US-20180118714-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | CYP3A4, ERG28, CYP4Z1 | CYP3A4 1/4885CYP2C9 47/4885CYP2C19 31/4885 |
| US-20170129874-A1 | NOVEL IMPROVED PROCESS FOR PREPARING A TRIAZOLE ANTIFUNGAL AGENT | ERG28, CYP51A1, CYP4F11 | CYP3A4 7/4885CYP2C9 38/4885CYP2C19 25/4885 |
| US-10626115-B2 | Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents | DHFR, SAMHD1, TYMP | CYP3A4 209/4885CYP2C9 953/4885CYP2C19 309/4885 |
| US-20190292166-A1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | CYP4B1, ERG28, CYP4F3 | CYP3A4 6/4885CYP2C9 50/4885CYP2C19 44/4885 |
| US-20130150586-A1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | CACNA1I, MED1, ADH1A | CYP3A4 304/4885CYP2C9 715/4885CYP2C19 1130/4885 |
| US-10479776-B2 | Process for the preparation of Efinaconazole | CYP3A4, ERG28, CYP4Z1 | CYP3A4 1/4885CYP2C9 47/4885CYP2C19 31/4885 |
| US-20190002467-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES CONTAINING BRIDGED NITROGEN, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | SAMHD1, DHFR, TYMP | CYP3A4 273/4885CYP2C9 1342/4885CYP2C19 566/4885 |
| US-20200181110-A1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | CYP4B1, ERG28, CYP4F3 | CYP3A4 6/4885CYP2C9 50/4885CYP2C19 44/4885 |
| US-10829475-B2 | Production and purification methods for efinaconazole | CYP4B1, ERG28, CYP4F3 | CYP3A4 6/4885CYP2C9 50/4885CYP2C19 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.